Study of EIS-12656 for solid tumors with DNA repair defects
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, EIS-12656, alone or with other treatments, for solid tumors that have specific DNA repair problems called homologous recombination deficiency. It may be an option if your cancer has not responded to prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer is advanced or has spread and cannot be removed by surgery
- Your tumor has a DNA repair defect called homologous recombination deficiency
- You have tried at least one prior treatment, or you cannot take standard therapies
- You have tumors that can be measured on scans
- You are in good overall health (ECOG score 0 or 1) and your organs are working well
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IMP1734 for people with advanced breast, ovarian, or prostate cancer that has a specific genetic change called an HRR mutation. The drug targets a protein called PARP1 to try to stop cancer cells from repairing themselves.
This early-phase study tests XL309 (and sometimes a mix of XL309 with another treatment) in people whose advanced solid tumors have specific DNA-repair gene changes, such as BRCA1/2 or other HRR-related changes. It aims to see how well the drug works and what dose is safest for these cancers.
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
This study tests a new drug (HSK46256) for people with advanced solid tumors that have a specific DNA repair gene change (HRR mutation). It is a first-in-human trial to find the right dose and check safety, so it may be an option if other treatments have stopped working.
This trial is testing a new drug (EIK1004) designed to block a protein called PARP1, which helps repair DNA. It is for people with advanced solid tumors, especially those with BRCA or other DNA repair gene mutations. The goal is to see if it can shrink tumors or slow their growth.
This trial tests a new drug called AZD4956, alone or with other cancer medicines, for people with advanced solid tumors that have certain DNA repair problems (called homologous recombination deficiency). It may be an option if you have breast, ovarian, prostate, or pancreatic cancer with a specific gene change, and you have or haven't had previous PARP inhibitor treatment.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.